NeoGenomics, Inc. (NASDAQ: NEO) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $2.0B. The Maz Rating grades it against the other companies in its sector.
NeoGenomics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.25, NeoGenomics, Inc. trades at 2.5x sales and 2.4x book value, with an EV/EBITDA of 71.2. Over the last twelve months it generated about $790M of revenue and a net loss of $32M. It runs a gross margin of 43.8%, an operating margin of -6.0% and a net margin of -4.1%. It shows return on equity of -4.0%, return on invested capital of -3.3% and a free cash flow yield of -1.4%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 3.53. Over the past 52 weeks the share price ranged from $7.07 to $20.15, with a beta of 1.83.
NeoGenomics, Inc. does not currently pay a dividend.
30 Wall Street analyst ratings cover the stock: 1 Strong Buy, 23 Buy, 5 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, NeoGenomics, Inc. (NEO) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 83.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 31.0% / 30% · Interest income / Revenue 0.57% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 83.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 31.0% / 33% · Receivables / Mkt Cap (36m) 47.4% / 49% · Interest income / Revenue 0.57% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 83.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 31.0% / 33.33% · Receivables / Mkt Cap (24m) 47.4% / 33.33% · Interest income / Revenue 0.57% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 27.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 10.9% / 33.33% · Receivables / Avg Assets (4Q) 13.2% / 33.33% · Interest income / Revenue 0.57% / 5% | Pass |
| FTSE | Debt / Total Assets 27.2% / 33.33% · (Cash+ST Inv) / Total Assets 10.1% / 33.33% · (Cash+Recv) / Total Assets 25.6% / 33.33% · Interest income / Revenue 0.57% / 5% | Pass |
It depends on the standard you follow. As of September 2026, NeoGenomics, Inc. (NEO) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. NeoGenomics, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 0.57% of each dividend: NeoGenomics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.